Stockreport

ZyVersa Therapeutics Reports Second Quarter, 2024 Financial Results and Provides Business Update

ZyVersa Therapeutics, Inc.  (ZVSA) 
PDF KEY HIGHLIGHTS Phase 2a clinical trial for Cholesterol Efflux Mediatorâ„¢ VAR 200 in patients with diabetic kidney disease on track to begin H2-2024.Obesity with related [Read more]